In this issue, we describe the numerous benefits of incorporating a stable isotope labelled internal standard for quantitative liquid chromatography-mass spectrometry, and detail recent advances in MS technology. Several case studies are presented, which exemplify novel bioanalytical workflows that are required to meet the challenges faced in both non-clinical and clinical development, across a variety of drug classes.

- 0:42 Introduction

- 5:33 The Case for Stable Isotope Labelled Internal Standards for LCMS Quantitation

- 8:34 Recent Innovations in Mass Spectrometry

- 15:38 Case Study: Dried Blood Microsampling

- 17:14 Case Study: Anti-Epileptic Drug Panel

- 19:17 Case Study: COVID-19 Neutralizing Monoclonal Antibody

- 21:16 Case Study: Differential Mobility Spectrometry (DMS)

- 23:49 Case Study: Bioequivalence

- 26:22 Case Study: Oligonucleotides

- 33:57 Conclusion

Click here to download a readable, PDF version of Issue 13: https://www.altasciences.com/sites/default/files/2022-12/The-Altascientist-issue-30-LCMS.pdf

About Altasciences:

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.